Lilly bracing for global demand for its experimental antibody for COVID-19
Shares of Lilly jumped 3.7%, or $5.41, to $149.54 in afternoon trading following the company’s morning announcement that it has asked the U.S. government to allow emergency use of the therapy to treat the disease.